Recruiting Brain Cancer Studies in Baltimore
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pem...
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier prope...
Combination Therapy for the Treatment of Diffuse Midline Gliomas
This phase II trial determines if the combination of ONC201 with different drugs, panobinostat or paxalisib, is effective for treating participants with diffuse midline gliomas (DMGs). Despite years o...
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying ...
Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme
In this study patients will be treated with 6 weeks of radiation therapy plus temozolomide chemotherapy according to the standard of care. However, the radiation treatment plan will be modified to del...
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy. Your participation could las...
Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
The objective of this study is to assess the tolerability, safety, and efficacy of Liposomal Curcumin (LC) in combination with radiotherapy (RT) and Temozolomide (TMZ) in patients with newly diagnosed...
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients w...
About Brain Cancer Clinical Trials in Baltimore
Brain cancer includes tumors that originate in the brain (primary) or spread from other areas (metastatic). Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Treatment typically combines surgery, radiation, and chemotherapy, with immunotherapy trials underway.
There are currently 8 brain cancer clinical trials recruiting participants in Baltimore, MARYLAND. These studies are seeking a combined 1,967 participants. Research is being sponsored by NovoCure GmbH, CarThera, University of California, San Francisco and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Brain Cancer Clinical Trials in Baltimore — FAQ
Are there brain cancer clinical trials in Baltimore?
Yes, there are 8 brain cancer clinical trials currently recruiting in Baltimore, MARYLAND. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Baltimore?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Baltimore research site will contact you about next steps.
Are clinical trials in Baltimore free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Baltimore studies also compensate for your time and travel.
What brain cancer treatments are being tested?
The 8 active trials in Baltimore are testing new therapies including novel drugs, biologics, and treatment approaches for brain cancer.
Data updated March 2, 2026 from ClinicalTrials.gov